Owen McCarty: The Potential Benefit of Targeting FXI in Sepsis
Owen McCarty, Professor and Chair at Oregon Health and Science University, shared a post on LinkedIn:
“Our recent preclinical work highlighting the potential benefit of targeting FXI in sepsis. Led by Robert Silasi and Ravi Shankar Keshari, Ph.D with Aleksandr Shamanaev, Samantha (Sami) Moellmer, Cristina Puy Garcia, PhD, Joseph Shatzel, and Florea Lupu.”
Title: Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis
Authors: Robert Silasi, Ravi S. Keshari, Tomohiro Abe, Stephanie D. Byrum, Girija Regmi, Cristina Lupu, Constantin Georgescu, Joe H. Simmons, Aleksandr Shamanaev, Samantha A. Moellmer, Cristina Puy, Joseph J. Shatzel, Dennis Province, Rick D. Edmondson, Samuel G. Mackintosh, Nathan L. Avaritt, Dan Bloomfield, David Gailani, Alan J. Tackett, Owen J.T. McCarty, Florea Lupu
Read full artile here.
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis